

# ELISA-VIDITEST

## anti-SARS-CoV-2 (NP) IgG

REF

ODZ-470



96 tests



2° - 10 °C

**Type of determination:** IgG antibodies

**Type of evaluation:** Qualitative, Semiquantitative

**Type samples:** Serum/Plasma

**Processing:** Manual and/or automatic

VIDIMAT 

CE 





# **ELISA-VIDITEST anti- SARS-CoV-2 (NP) IgG**

**ODZ-470**

## **Instruction manual**

**PRODUCER:** VIDIA spol. s r.o., Nad Safinou II 365, 252 50 Vestec, Czech Republic, tel.: +420 261 090 565, www.vidia.cz

### **1. TITLE:**

ELISA-VIDITEST anti-SARS-CoV-2 (NP) IgG – ELISA kit for the detection of IgG antibodies to nucleocapsid protein (NP) of coronavirus SARS-CoV-2, causing the COVID-19 disease in human serum and plasma.

### **2. INTRODUCTION:**

After infection of a human body with the SARS-CoV-2 virus, the antibodies to this virus appear in the patient's blood. Most persons infected with SARS-CoV-2 display an antibody response between day 10 and day 21 after infection. Detection in mild cases can take longer time (four weeks or more) and in a small number of cases antibodies (i.e., IgM, IgG) are not detected at all (at least during the studies' time scale). Based on the currently available data, the IgM and IgG antibodies to SARS-CoV-2 develop between 6–15 days post disease onset. The presence of antibodies was detected in <40% among patients within 1 week from onset, and rapidly increased to 100% (total antibodies), 94.3% (IgM) and 79.8% (IgG) from day-15 after onset.

The longevity of the antibody response is still unknown, but it is known that antibodies to other coronaviruses wane over time (range: 12 – 52 weeks from the onset of symptoms) and homologous re-infections have been shown. SARS-CoV-2 IgM and IgG antibody levels may remain over the course of seven weeks or at least in 80% of the cases until day 49. In comparison, 90% and 50% of SARS-CoV-1 infected patients have been shown to maintain IgG antibodies for two and three years respectively. In addition, it could be important to detect nasal IgA antibodies, as the serum IgA antibodies were not raised, but IgA persisted in the nasal mucosa one year post-infection for seasonal coronavirus 229E.

The presence of antibodies against SARS-CoV-2 does not indicate the protection to COVID-19, a correlation between blood antibody levels and immunity has not been established. Long-term serological studies will be required for this purpose.

### **3. TEST PRINCIPLE:**

ELISA-VIDITEST anti-SARS-CoV-2 (NP) IgG is a solid-phase immunoanalytical test. The specific antigen (Nucleocapsid Protein) is fixed to each well of the microtiterstrips. Specific antibodies present in the patient's sample are bound during the first incubation step. After removing unbound material by washing, the presence of the specific antibodies is detected using anti-human IgG conjugate during the second incubation. The unbound peroxidase conjugate is then removed and TMB substrate is added, resulting in the development of a blue colour in positive samples. The

enzyme reaction is terminated by addition of the stop solution (colour change to yellow). The intensity of the yellow colour thus developed is proportional to the concentration of antibodies in the sample.

#### 4. KIT COMPONENTS:

|  |           |            |
|--|-----------|------------|
| ELISA break-away strips in the handling frame coated with the antigen                                  | STRIPS Ag | 1 x 12 pcs |
| 1.3 mL Negative control serum, r.t.u.  | NC        | 1 vial     |
| 1.3 mL Positive control serum, r.t.u.  | PC        | 1 vial     |
| 1.3 mL Calibrator, r.t.u. <sup>1)</sup>  | CAL       | 1 vial     |
| 13 mL Anti-human IgG antibodies labelled with horseradish peroxidase<br>(anti-IgG Px conjugate) r.t.u. | CONJ      | 1 vial     |
| 55 mL Wash buffer, 10x concentrated  | WASH 10x  | 1 vial     |
| 60 mL Dilution buffer, r.t.u.  | DIL       | 1 vial     |
| 13 mL Chromogenic substrate TMB, r.t.u.  | TMB       | 1 vial     |
| 13 mL Stop solution, r.t.u.  | STOP      | 1 vial     |
| Instruction manual   |           |            |
| Certificate of quality   |           |            |
| <sup>1)</sup> r.t.u., ready to use   |           |            |

**Notice:** Control sera may be colorless to yellowish or blue due to the use of different diluents.

Chromogenic substrate **TMB** is compatible and interchangeable between ELISA-VIDITEST kits which contain **TMB** and not compatible with other Chromogenic substrates used in other ELISA-VIDITEST **TMB-O**, **TMB-BF**.

#### 5. MATERIALS AND EQUIPMENT REQUIRED BUT NOT PROVIDED:

Distilled or deionised water for dilution of the Wash buffer concentrate, appropriate equipment for pipetting, liquid dispensing and washing, spectrophotometer/colorimeter (microplate reader – filter with wavelength 450 nm and 620-690 nm reference filter (not required)).

The test can be performed automatically using the VIDIMAT analyzer.

#### 6. PREPARATION OF REAGENTS AND SAMPLES:

- a. Allow all kit components to reach laboratory temperature.
- b. Vortex Solutions, Controls and Peroxidase conjugate in order to ensure homogeneity.
- c. Vortex sera and plasma samples and Controls well prior use. In the automatic analyzer VIDIMAT the dilution of samples is performed automatically (pre-set dilution for serum and plasma samples is 101x). In the case of manual performance of the test dilute serum samples 101x in Dilution buffer (e.g. 5 µL of serum sample + 500 µL of Dilution buffer). Do not dilute the Controls, they are ready to use.
- d. Prepare Wash buffer by diluting the Wash buffer concentrate 10 times with an appropriate volume of distilled or deionised water (e.g. 50 mL of the concentrated Wash buffer + 450 mL of distilled water). If there are crystals of salt present in the concentrated Wash buffer, warm up the vial to +32 to +37 °C in a water bath. Diluted Wash buffer is stable for one month if stored at laboratory temperature.
- e. Do not dilute the Controls, Peroxidase conjugate, Chromogenic substrate **TMB** and Stop solution, they are ready to use.

## 7. ASSAY PROCEDURE:

**Manufacturer will not be held responsible for results if manual is not followed exactly.**

### 7.1 Assay procedure for manual performance

- a. Allow the vacuum-closed strips in bag with desiccant to reach a laboratory temperature before opening, to avoid dew condensation. Withdraw the adequate number of strips for reaction. Put unused strips into the provided pouch and seal it carefully with the desiccant kept inside.
- b. Pipette 100 µL of control sera and diluted tested samples to the wells according to the pipetting scheme (see in Tab 1): start with filling the first well dilution buffer (DIL), the next two wells with Calibrator **CAL**, next well with Positive control serum **PC** and another one well with Negative control serum **NC** and the remaining wells with tested samples (S1, S2, ...). It is sufficient to apply samples as singlets, however, if you wish to minimize laboratory error apply the calibrator **CAL** in triplet and the samples in doublets.

Incubate **60 minutes** (±5 min) at laboratory temperature.

- c. Aspirate the liquid from wells into a collecting bottle containing appropriate disinfectant (see Safety Precautions). Wash and aspirate the wells four times with 250 µL/well of Wash buffer. Avoid cross-contamination between wells. Aspirate the contents of the wells and invert the plate and tap it on an adsorbent paper to remove the last remaining drops.
- d. Add 100 µL Peroxidase conjugate anti-IgG Px r.t.u. **CONJ** into each well. Incubate **30 minutes** (±2 min) at laboratory temperature..
- e. Aspirate and wash four times with 250 µL/well of Wash buffer as in section c above.
- f. Dispense 100 µL of **TMB** chromogenic substrate into each well. **Incubate 15 minutes** (±30 seconds) at laboratory temperature. **The time measurement must be started at the beginning of **TMB** dispensing to the first well of the plate.** Follow this rule to avoid breaking the time interval. Pipette quickly at regular rhythm, or use a suitable dispenser. Cover the strips and keep them in the dark during the incubation with **TMB** substrate.
- g. Stop the reaction by adding 100 µL of Stop solution **STOP**. Use the same pipetting rhythm as with the **TMB** to ensure the same reaction time in all wells. Tap gently the microplate for a few times to ensure complete mixing of the reagents. Before measuring ensure that the bottom of the wells is clean and the wells of the ELISA plate is without air bubbles.
- h. Read the absorbance at 450 nm with a microplate reader **within 20 minutes**. It is recommended to use a reference reading at 620 - 690 nm.

Tab. 1: Pipetting scheme

|   | 1   | 2    | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
|---|-----|------|---|---|---|---|---|---|---|----|----|----|
| a | DIL | S4   |   |   |   |   |   |   |   |    |    |    |
| b | CAL | S... |   |   |   |   |   |   |   |    |    |    |
| c | CAL |      |   |   |   |   |   |   |   |    |    |    |
| d | PC  |      |   |   |   |   |   |   |   |    |    |    |
| e | NC  |      |   |   |   |   |   |   |   |    |    |    |
| f | S1  |      |   |   |   |   |   |   |   |    |    |    |
| g | S2  |      |   |   |   |   |   |   |   |    |    |    |
| h | S3  |      |   |   |   |   |   |   |   |    |    |    |

## 7.2 Assay procedure for performance on VIDIMAT analyzer

In the automatic analyzer VIDIMAT the entire test is run automatically. For testing serum/plasma samples, please use the appropriate method stated in the **Quality Control Certificate** for specific kit lot.

**Before using the specific kit lot for the first time, it is necessary to set all parameters stated in the Quality Control Certificate for this kit lot.**

In the case of a parallel assay of anti-SARS-CoV-2 (NP) IgG and anti-SARS-CoV-2 (NP) IgM or anti-SARS-CoV-2 (NP) IgA kits, it is necessary to schedule the anti-SARS-CoV-2 (NP) IgM and then anti-SARS-CoV-2 (NP) IgG or anti-SARS-CoV-2 (NP) IgA methods.

The incubation conditions programmed in the software concerned may differ slightly from the specifications given in the instruction manual for the manually performed ELISA-VIDITEST test. These conditions have been validated by the manufacturer. Validation protocols are available on request.

It is possible to perform ELISA-VIDITEST tests using other automatic open analyzers, but this combination must be verified by the user himself.

## 8. PROCESSING OF RESULTS:

**The VIDIMAT analyzer performs the data evaluation automatically.**

Begin the processing of results with subtraction of the background absorbance (absorbance of the DIL well) from the absorbances of all other wells (controls and tested sera/plasma).

If the absorbance of controls or tested sera/plasma are negative after background subtraction, consider them as zero value.

### 8.1. Processing of results for the Qualitative interpretation

1. Compute the absorbance mean of the wells with Calibrator **CAL**. If the **CAL** was applied in three parallels and the absorbance in one well is different from the mean in more than 20%, then exclude the deviating well from the calculation and compute a new absorbance mean using the other two wells.

2. **Compute the cut-off value** by multiplying the mean absorbance of Calibrator with a correction factor. **The correction factor value for this lot is stated in the Quality control certificate.**

Serum samples with absorbances lower than the 90% of the cut-off value are considered negative and samples with absorbances higher than 110% of the cut-off value are considered positive. Serum samples with absorbance in the range 90% - 110% cut-off are equivocal (grey-zone) and then it is recommended to repeat testing or to test another sample from the patient, usually withdrawn 1-2 weeks later.

### 8.2. Processing of results for the Semiquantitative interpretation

Determine Positivity Index for each sample as follows:

1. Compute the **cut-off value** (see the previous paragraph, 8.1, point 2)
2. Compute the Positivity Index according to the following formula:

$$\text{sample Positivity Index} = \frac{\text{sample absorbance}}{\text{cut-off value}}$$

3. Express the serum reactivity according to INTERPRETATION OF RESULTS (see below).

## INTERPRETATION OF RESULTS:

| <u>Positivity index</u> | <u>Interpretation</u> |
|-------------------------|-----------------------|
| < 0.90                  | Negative              |
| 0.90 - 1.10             | +/-                   |
| > 1.10                  | Positive*             |

\*on the basis of the Positivity Index value it is possible to estimate semiquantitatively the amount of antibodies in the sample.

Example of calculation:

|                         |                        |
|-------------------------|------------------------|
| CAL absorbances         | = 1.063; 0.987; 1.025  |
| CAL mean                | = 1.025                |
| Sample absorbance       | = 0.800                |
| Correction factor       | = 0.32                 |
| Cut-off value           | = 1.025 x 0.32 = 0.328 |
| Sample Positivity Index | = 0.800 / 0.328 = 2.44 |

*Note: An indifferent sample reactivity, i.e. interpreted as +/-, requires repetition of the sample testing. If the result is again indifferent then it is recommended to use an alternative testing method or to obtain another sample from the patient, usually withdrawn 1-2 weeks later.*

## 9. CHARACTERISTICS OF THE TEST:

The kit is intended for the qualitative and semiquantitative detection of anti-SARS-CoV-2 IgG antibodies in human serum and plasma. Suitable specimens are serum (heparinised) and plasma samples obtained by standard laboratory techniques. The samples may be heat-inactivated (56°C, 30min), high temperature inactivation does not affect the results.

### 9.1. Validity of the test

The background of the reaction (the absorbance of the Dilution buffer [DIL]) is less than 0.150.

The mean absorbance values of standards/ control sera, and the ratio between the absorbance values of [PC] / [CAL] are in the ranges stated in the Quality control certificate for this kit lot

### 10.2. Precision of the test

The intraassay variability (within the test) and the interassay variability (between tests) were determined by testing samples with different OD values.

#### 9.2.1 Intraassay variation

The coefficient of intraassay variability is max. 8%. It is measured for each particular Lot at least on 8 parallels of the same microtitration plate.

Example: (n = number of parallels of the same microtitration plate)

| n | A     | $\pm\sigma$ | CV%   |
|---|-------|-------------|-------|
| 8 | 1.735 | 0.073       | 4.2 % |
| 8 | 1.523 | 0.062       | 4.1 % |

#### 9.2.2 Interassay variability

The coefficient of interassay variability is max. 15%. It is measured for each particular Lot as comparison of the OD values of the same serum sample in several consecutive tests.

Example: (n = number of an independent examination of the same sample):

| n | A     | $\pm\sigma$ | min-max     | CV%  |
|---|-------|-------------|-------------|------|
| 6 | 1.863 | 0.102       | 1.746-2.032 | 5.5% |
| 6 | 1.673 | 0.119       | 1.525-1.846 | 7.1% |

### 9.2.3 Recovery test

Measured values of recovery test for every Lot are between 80-120% of expected values.

### 9.3. Diagnostic sensitivity and specificity of the test

Diagnostic sensitivity of the test is 96% and diagnostic specificity is 97%. Evaluation was performed on positive and negative patient samples tested with another commercially available diagnostic test (ELISA).

The samples with the equivocal results were not included in the calculation.

### 9.4. Interference

Haemolytic and lipemic samples have no influence on the test results up to concentration of 50 mg/mL of haemoglobin, 5 mg/mL of bilirubin and 50 mg/mL of triglycerides, but examination of such a samples is not recommended.

Microbial contaminated specimen may cause interferences.

## 10. SAFETY PRECAUTIONS:

All ingredients of the kit are intended for laboratory use only.

The human sera used in LISA kit have been tested negative for HBsAg, anti-HIV-1,2 and anti-HCV. Nevertheless, treat them as infectious material and objects that came into contact with them, autoclave at 121 ° C for 1 hour, or disinfect for at least 30 minutes with a 3% chloramine solution.

Liquid wastes containing acid (Stop solution) should be neutralized in 4% sodium bicarbonate solution.

Handle Stop solution with care. Avoid contact with skin or mucous membranes. In case of contact with skin, rinse immediately with plenty of water and seek medical advice, if necessary.

The waste from washing of the strips disinfect a waste container using a suitable disinfectant solution (eg Incidur, Incidin, chloramine,...) at the concentration recommended by the manufacturer.

Do not smoke, eat or drink during work. Do not pipette by mouth. Wear disposable gloves while handling reagents or samples and wash your hands thoroughly afterwards. Avoid spilling or producing aerosol.

## 11. HANDLING PRECAUTIONS:

- Manufacturer guarantees performance of the entire ELISA kit.
- Wash solution, TMB chromogenic substrate r.t.u., Stop solution r.t.u. and Dilution buffer r.t.u. are compatible and interchangeable between different ELISA-VIDITEST kits except those with different instruction in its Instruction Manual.
- Work aseptically to avoid microbial contamination of sera and reagents.
- When collecting, diluting, and storing reagents, be careful not to cross-contaminate them or contaminate them with enzymatic activity inhibitors. Avoid microbial contamination of serum samples and kit reagents. Avoid cross-contamination of reagents.
- Calibrator and control sera contain preservative ProClin 300 (mix of 5-Chloro-2-methyl-4-isothiazolin-3-one a 2-Methyl-2H-isothiazol-3-one (3:1)).
- Avoid contact of the TMB with oxidizing agents or metal surfaces.

- g. Follow the assay procedure indicated in the Instruction manual. Variations in the test results are usually due to:
- \* Insufficient mixing and prewarming to room temperature of reagents and samples
  - \* Inaccurate pipetting and inadequate incubation times
  - \* Poor washing technique or spilling the rim of well with sample or Peroxidase conjugate
  - \* Use of identical pipette tip for different solutions
  - \* Contamination of pipette used for the administration of samples, controls or chromogen substrate solution TMB, Px conjugate (we recommend using pipette which is only reserved for the conjugate application).

## 12. STORAGE AND EXPIRATION:

**The ELISA kit should be used within three months after opening.**

- a. Store the kit and the kit reagents at +2 to +10°C, in a dry place and protected from the light. Under these conditions, the expiration period of the entire kit is indicated on the central label, the expiration date of the individual components is indicated on their package labels.
- b. Store unused strips in the sealable pouch and keep the desiccant inside.
- c. Kits are shipped in cooling bags, the transport time up to 72 hours have no influence on expiration. If you find damage at any part of the kit, please inform the manufacturer immediately.
- d. Store undiluted sera in aliquots at -18 to -28 °C. Frequent freezing and thawing is not recommended. Undiluted serum samples could be stored at +2 to +10°C up to one week.
- e. Do not store diluted samples. Always prepare fresh.

## 13. USED SYMBOLS:

 number of tests

 Conformité Européenne – product meets the requirements of European legislation

 in vitro diagnostics

$\pm\sigma$  standard deviation

CV coefficient of variation

OD optical density

 manufacturer

 expiration

 Lot of kit

 storage at +2°C to +10°C

°C Celsius degree

% percentage

n number of tested samples


A value of tested sample

 read usage instructions



catalog number

#### 14. FLOW CHART:



#### General references:

<https://www.ecdc.europa.eu/en/covid-19/latest-evidence/immune-responses>

Woelfel R. et al.: Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travel-associated transmission cluster. medRxiv. 2020:2020.03.05.20030502

Zhao J. et al.: Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. medRxiv. 2020:2020.03.02.20030189

Okba N.M.A. et al.: SARS-CoV-2 specific antibody responses in COVID-19 patients. medRxiv. 2020:2020.03.18.20038059

Liu W. et al.: Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2. medRxiv.2020:2020.03.16.20035014

Long Q. et al.: Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice. medRxiv.2020:2020.03.18.20038018

Wan W.Y. et al.: Cross-reaction of sera from COVID-19 patients with SARS-CoV assays. medRxiv. 2020:2020.03.17.20034454

Zhao J. et al.: Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. *Clinical Infectious Diseases*. 2020

Kellam P., Barclay W.: The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. *The Journal of general virology*. 2020 May 20

Xiao A.T. et al.: Profile of specific antibodies to SARS-CoV-2: The first report. *The Journal of infection*. 2020 Mar 21

Zeng H. et al.: Antibodies in Infants Born to Mothers With COVID-19 Pneumonia. *JAMA*. 2020

Wu L.P. et al. Duration of antibodyresponses after severe acute respiratory syndrome. *Emerging infectious diseases*. 2007;13(10):1562-4

Callow K.A. et al.: The time course of the immune response to experimental coronavirus infection of man. *Epidemiol Infect*. 1990;105(2):435-46

Neil M. Ferguson et al.: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand: Imperial College; 2020 [updated 16 March, 2020; cited 2020 23 March, 2020]. Available from: <https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gidafellowships/Imperial-College-COVID19-NPI-modelling-16-03-2020.pdf>.

Li G. et al. (2020) Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). <https://doi.org/10.1093/cid/ciaa310>

Burbelo D. et al. (2020) Detection of Nucleocapsid Antibody to SARS-CoV-2 is more sensitive than antibody to spike protein in COVID-19 Patients. <https://doi.org/10.1101/2020.04.20.20071423>

Weihong Z., et al. (2020) Biochemical characterization of SARS-CoV-2 nucleocapsid protein. <https://doi.org/10.1016/j.bbrc.2020.04.136>.

Date of the last revision of this manual: 02/2021

